¿ Biotrin International Ltd., of Dublin, Ireland, said its Parvovirus B19 enzyme immunoassay tests were cleared for sale in the U.S. by the FDA. The agency recommended approval for use in pregnant women.
¿ Cambridge Combinatorial Ltd., of Cambridge, England, agreed to a deal with Yamanouchi Pharmaceuticals Ltd., of Tokyo, to design and synthesize compounds aimed at two undisclosed targets. The company, which is a subsidiary of Oxford Molecular Group plc, said the collaboration included research fees, milestones and royalties.
¿ Oxford Molecular Group plc, of Oxford, England, released results for the six months ended June 30, 1999, showing revenues of #10.16 million, ahead 31 percent from the same period in 1998. The company said sales of its bioinformatics software were higher than expected. The overall loss was #4.1 million, up from #2.8 million, which the company attributed to the costs of running its subsidiary, Cambridge Combinatorial Ltd.